The delivery of liquid and solid vaccine formulations to developing countries entails several challenges, one of which is cold chain breaks. Short-term exposure to higher temperatures of up to 50 – 80° C results in a large proportion of these vaccines being wasted each year. It is in the interest of patients and manufacturers alike as the latter faces the financial risk of wasted vaccines. Additionally, approval of new vaccines is restricted due to the pressure on the supply chain.
Therefore, we asked ourselves: How can we stabilize protein vaccines in liquid and solid formulations towards these temperature increases using conventional and new excipients?
In this webinar, you will learn:
- About the challenges involved in the delivery of vaccines to developing countries and potential risks
- How using conventional and new excipients can stabilize protein vaccines in liquid and in solid vaccine formulations upon short-term cold chain breaks
Speaker
Michelle Pascale Zoeller
Merck
Senior Scientist
Michelle Zoeller is a senior scientist focusing on novel modality formulation at Merck. She has 6 years of experience in the field of parenteral formulations of proteins and novel modalities. Michelle holds an M.Sc. in biomolecular engineering from TU Darmstadt. She then participated in a joint Ph.D. program between Merck, Heidelberg University, and the Steinbeis Transfer Center of Biopharmacy and Analysis, during which she worked on the characterization of novel surfactants for the formulation of therapeutic proteins.
Pharma and biopharma manufacturing
- Liquid Formulation Strategies
Dauer:36min
Sprache:English
Sitzung 1:vorgestellt October 5, 2023
Um weiterzulesen, melden Sie sich bitte an oder erstellen ein Konto.
Sie haben kein Konto?